Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 15;20(1):756.
doi: 10.1186/s12879-020-05458-w.

Pre-HAART CD4+ T-lymphocytes as biomarkers of post-HAART immune recovery in HIV-infected children with or without TB co-infection

Affiliations

Pre-HAART CD4+ T-lymphocytes as biomarkers of post-HAART immune recovery in HIV-infected children with or without TB co-infection

Vivek Gopalakrishnan et al. BMC Infect Dis. .

Abstract

Background: Infection with the Human Immunodeficiency Virus (HIV) dramatically increases the risk of developing active tuberculosis (TB). Several studies have indicated that co-infection with TB increases the risk of HIV progression and death. Sub-Saharan Africa bears the brunt of these dual epidemics, with about 2.4 million HIV-infected people living with TB. The main objective of our study was to assess whether the pre-HAART CD4+ T-lymphocyte counts and percentages could serve as biomarkers for post-HAART treatment immune-recovery in HIV-positive children with and without TB co-infection.

Methods: The data analyzed in this retrospective study were collected from a cohort of 305 HIV-infected children being treated with HAART. A Lehmann family of ROC curves were used to assess the diagnostic performance of pre- HAART treatment CD4+ T-lymphocyte count and percentage as biomarkers for post-HAART immune recovery. The Kaplan-Meier estimator was used to compare differences in post-HAART recovery times between patients with and without TB co-infection.

Results: We found that the diagnostic performance of both pre-HARRT treatment CD4+ T-lymphocyte count and percentage was comparable and achieved accuracies as high as 74%. Furthermore, the predictive capability of pre-HAART CD4+ T-lymphocyte count and percentage were slightly better in TB-negative patients. Our analyses also indicate that TB-negative patients have a shorter recovery time compared to the TB-positive patients.

Conclusions: Pre-HAART CD4+ T-lymphocyte count and percentage are stronger predictors of immune recovery in TB-negative pediatric patients, suggesting that TB co-infection complicates the treatment of HIV in this cohort. These findings suggest that the detection and treatment of TB is essential for the effectiveness of HAART in HIV-infected pediatric patients.

Keywords: CD4+ T-lymphocytes; immune recovery; HAART; HIV; ROC curves; TB.

PubMed Disclaimer

Conflict of interest statement

Musie Ghebremichael is an editorial board member of BMC Infectious Diseases journal. Other authors do not have a commercial or other association that might pose a conflict of interest, i.e., authors declare that they have no competing interests to disclose.

Figures

Fig. 1
Fig. 1
Kaplan-Meier estimates of time until immune recovery for HIV-infected patients with and without TB co-infection
Fig. 2
Fig. 2
Distribution of pre-HAART CD4+ T-lymphocyte counts and percentages by post-HAART immune recovery status. The lower and upper panels of the figure are for patients who achieved and failed to achieve post-HAART immune recovery, respectively
Fig. 3
Fig. 3
ROC curves for pre-HAART CD4+ T-lymphocyte counts and percentages
Fig. 4
Fig. 4
ROC curves for pre-HAART CD4+ T-lymphocyte counts and percentages by TB status. The left and right panels of the figure are for TB-negative and TB-positive patients, respectively

Similar articles

Cited by

References

    1. Joint United Nations Programme on HIV/AIDS. Global AIDS monitoring 2019: indicators for monitoring the 2016 political declaration on ending AIDS. 2018.
    1. Health TNI Of. Clinical and Laboratory Monitoring of Pediatric HIV Infection https://aidsinfo.nih.gov/guidelines/brief-html/2/pediatric-arv/59/clinic.... Accessed 5 June 2020.
    1. Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2019. 2019. https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_.... - PubMed
    1. Zachariah R, Reid SD, Chaillet P, Massaquoi M, Schouten EJ, Harries AD. Viewpoint: why do we need a point-of-care CD4 test for low-income countries?: why do we need a point-of-care CD4 test for low-income countries? Tropical Med Int Health. 2011;16:37–41. doi: 10.1111/j.1365-3156.2010.02669.x. - DOI - PubMed
    1. Malkin R, Keane A. Evidence-based approach to the maintenance of laboratory and medical equipment in resource-poor settings. Med Biol Eng Comput. 2010;48:721–726. doi: 10.1007/s11517-010-0630-1. - DOI - PubMed

MeSH terms